Femasys is trading at $2.85 (6.9% down) amid profit-taking and ongoing volatility following recent price swings.
- The decline follows a sharp 17.5% drop in the previous session and a brief technical rebound during pre-market trading.
- There is no fresh fundamental company news reported, suggesting the stock's weakness is idiosyncratic as the broader biotechnology sector trends higher.